BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.25 +0.34 (+0.51%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Why BioMarin Shares Are Plunging Today? ↗

March 06, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

Via Benzinga

These 2 Biotech Stocks Made Big Monday Moves ↗

March 06, 2023

Find out which was the winner and which was the loser.

Via The Motley Fool

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations ↗

March 06, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today? ↗

March 06, 2023

BBIO stock looks unstoppable today as BridgeBio Pharma diligently advances a treatment for a rare and unfortunate condition.

Via InvestorPlace

Looking Into BridgeBio Pharma's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher ↗

March 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...

Via Benzinga

Why BridgeBio Pharma Stock Is Skyrocketing Today ↗

March 06, 2023

BridgeBio's latest results could set the bar in efficacy for treating the most common cause of short stature.

Via The Motley Fool

Stocks Rise As Bond Yields Fall; Investors Await Economic Data ↗

March 06, 2023

Wall Street is starting the week higher, as investors look ahead to upcoming economic data and new commentary from the Federal Reserve.

Via Talk Markets

BridgeBio's Dwarfism Candidate Shows Favorable Height Increase, Safety Profile ↗

March 06, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the...

Via Benzinga

What's Going On With Kala Pharmaceuticals Shares Today ↗

March 06, 2023

Kala Pharmaceutical (NASDAQ: KALA) shares skyrocketed more than 20% Monday morning on higher-than-average volume. On an average market day, Kala shares trade about 2.5 million times throughout the...

Via Benzinga

Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

March 06, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

What's Going On With Avalon GloboCare Shares Today ↗

March 06, 2023

The overall market ticked slightly higher in pre-market trading Monday morning, but Avalon Globocare Corp (NASDAQ: ALBT) shares really took off. Avalon GloboCare is a biotech company headquartered in...

Via Benzinga

Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January ↗

March 06, 2023

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday ↗

March 06, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events

March 06, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

March 03, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

February 23, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 17, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 16, 2023

Via Benzinga

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

February 13, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Participate in February and March Investor Events

February 08, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

January 04, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗

February 06, 2023

Via Benzinga

Why BridgeBio Pharma Stock Is Shooting Higher ↗

December 29, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else?

Via Benzinga

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

December 22, 2022

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗

December 29, 2022

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.